Publication
Article
Oncology & Biotech NewsDecember 2010
Volume 4
Issue 12
FDA Requests Label Change for Generic Docetaxel
Author(s):
The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.
The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel, which is currently being considered for FDA approval. The change is needed because Hospira’s version of the drug will be supplied in two 10-mg/mL vials, rather than in a single 20-mg/mL vial, which the FDA has said sanofi-aventis is permitted to use when selling Taxotere, its branded version of docetaxel.
Articles in this issue
Medulloblastoma Subtypes Are Different Diseases
ASH 2010: CPX-351 Improves Response in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myeloma
ASH 2010: Intensified R-ACVBP More Effective and More Toxic Than R-CHOP in Diffuse Large B-Cell Lymphoma
ASH 2010: Carfilzomib Shrinks Tumors in More Than One-Third of Pretreated Myeloma Patients
ASH 2010: Brentuximab Vedotin Produces High Response Rate in Relapsed or Refractory Hodgkin Lymphoma
ASH 2010: Bosutinib Shows Promise as First-line Treatment of Chronic Myelogenous Leukemia
ASH 2010: Multiple Benefits Observed for Bortezomib in Newly Diagnosed Myeloma Patients
FDA Green-Lights Phase III Trial for Drug-Eluting Microspheres in Liver Cancer
FDA Requests Label Change for Generic Docetaxel
FDA Considers Approval of Fusilev for Colorectal Cancer
Advisory Panel Discusses Expanded Indication for Avodart
FDA Approves Zactima
Effects of UV Radiation Are Cumulative
People in Britain Say Find Aliens, Cure Cancer
Related Videos
Related Content
